Chardan analyst Keay Nakae raised the firm’s price target on Alnylam (ALNY) to $475 from $400 and keeps a Buy rating on the shares following the Q3 report. The company’s early sales trajectory of Amvuttra for ATTR-CM is “impressive,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharmaceuticals Reports Strong Q3 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Alnylam Pharma’s Strong Q3 Performance and Promising Outlook Reinforce Buy Rating Despite Legal Concerns
- Alnylam price target raised to $495 from $475 at Morgan Stanley
- Alnylam price target lowered to $549 from $550 at Jefferies